bioAffinity Technologies

Home
United States
San Antonio, TX
bioAffinity Technologies

Addressing the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment. www.cypathlung.com

Our flagship product, CyPath® Lung, is a noninvasive early lung cancer diagnostic.

03/13/2026

Today, bioAffinity Technologies (Nasdaq: BIAF) reported financial results for the year ended December 31, 2025.

Revenue from CyPath® Lung, our noninvasive diagnostic for lung cancer, increased 87% over 2024, and the number of tests performed rose 99% year over year. Physician orders grew 67%, reflecting expanding adoption across clinical practices.

Strategic operational changes streamlined laboratory services, allowing the company to focus resources on CyPath® Lung as its core diagnostic offering.

Read the release: https://bwnews.pr/46ZlG7N

03/10/2026

bioAffinity Technologies (Nasdaq: BIAF) is proud to announce an important milestone with the initiation of a large-scale longitudinal study for CyPath® Lung. The study is an important step toward making CyPath® Lung a Standard of Care when diagnosing lung cancer.

Funded in part by the Murtha Cancer Center Research Program at Uniformed Services University, this 2,000-patient longitudinal study follows previous clinical results that showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients with small pulmonary nodules.

We are especially honored to be partnering with federal facilities and military hospitals for this study, bringing our noninvasive diagnostic test to diverse populations, including veterans and military service members.

Read the announcement: https://bit.ly/4bAG8OU

03/09/2026

New research presented at highlights how sputum-based testing can identify biologic drug receptors in sputum, helping clinicians determine the most effective treatment for patients with asthma.

Get it right the first time.

Read the article from Patient Care featuring bioAffinity Technologies Chief Scientific Officer William Bauta, PhD: https://bit.ly/4stC4FS

03/08/2026

Lung cancer is not always included in conversations about women’s health, but it should be. This International Women’s Day, we’re proud to be a woman-led team advancing innovation in lung cancer detection through our noninvasive CyPath® Lung diagnostic tool.

CyPath® Lung is a noninvasive test that helps physicians detect lung cancer sooner, provide clearer guidance, and involve patients in care decisions. By combining early insight with actionable information, we can reduce uncertainty, improve outcomes and help women take charge of their health. https://www.cypathlung.com/

03/06/2026

Interventional pulmonology continues to evolve with robotics and advanced diagnostic tools, but deciding when to intervene remains one of the most important clinical decisions.

Vamsi Guda, DO, uses CyPath® Lung to risk-stratify patients with small pulmonary nodules before moving toward more advanced interventions. By providing additional insight into malignancy risk, the test helps clinicians decide when to proceed and when monitoring may be appropriate.

That clarity supports earlier detection, more confident decisions, and a care pathway that prioritizes both patient safety and clinical precision.

Learn more: https://www.cypathlung.com/

03/04/2026

Lung cancer workups often rely on imaging and biopsy, but many patients don’t meet size thresholds for those steps early on.

Israel Elias Garcia, MSN, uses CyPath® Lung to supplement the diagnostic process and help provide earlier insight into malignancy risk and prognosis. The noninvasive, at-home collection process supports participation, while timely results help clinicians address patient questions and plan care with greater clarity.

By bringing patients into the decision-making process earlier, tools like CyPath® Lung support more informed conversations about monitoring, treatment planning, and next steps.

Learn more: https://www.cypathlung.com/

03/03/2026

New data presented at the American Academy of Allergy, Asthma, and Immunology 2026 annual meeting by our Chief Science Officer, William Bauta, PhD, highlights the ability of our innovative diagnostic approach to identify antibody drug receptors in sputum, including receptors for dupilumab, a leading therapy for asthma and COPD, and benralizumab, another asthma therapy.

Asthma and COPD impact approximately 650 million children and adults globally and many patients must try a series of therapies before finding one that works well for them.

We are leveraging our expertise in using our proprietary flow cytometry platform equipped with automated AI analysis to develop tests that match asthma and COPD patients with the most appropriate biologic therapies and monitor their ongoing conditions.

Read more about the new scientific poster presentation: https://bit.ly/4cYPt4f

02/26/2026

For pulmonologist Greg White, M.D. early lung cancer detection is only part of the challenge. The next step is deciding what to do when a nodule is found.

With a growing number of CT scans and more nodules to evaluate, Dr. White relies on CyPath® Lung to help risk stratify patients and inform whether to continue surveillance or move toward biopsy.

Clarity is critical in clinical environments where every decision affects both patient experience and outcomes. Learn more about the difference CyPath® Lung is making in noninvasive, early lung cancer diagnostics. https://cypathlung.com

02/25/2026

bioAffinity Technologies (Nasdaq: BIAF) announces a new study with Brooke Army Medical Center (BAMC) to validate the use of CyPath® Lung with sputum samples collected via tracheal and bronchial suction during routine clinical procedures.

The study is designed to assess whether samples collected during routine airway procedures may expand clinical utility for early lung cancer detection in high-risk patients.

Enrollment is expected to include 30–50 patients, with results anticipated mid-2026.

We look forward to advancing noninvasive approaches to earlier detection.

Read the full announcement: https://bit.ly/4cL7bbg

02/24/2026

Early detection can make all the difference in lung cancer, but indeterminate nodules often leave patients and clinicians waiting for clarity.

CyPath® Lung is a noninvasive test designed to support early insight for high-risk patients by analyzing the lung microenvironment and informing next steps in care.

Know More. Move Forward. https://www.cypathlung.com

02/19/2026

A new clinical case study from bioAffinity Technologies highlights how CyPath® Lung supported a recommendation for surveillance rather than subjecting an elderly, high-risk patient to an invasive biopsy after a suspicious lung nodule was identified.

The noninvasive test provided objective data to help guide clinical decision-making and support a conservative management approach. A follow-up scan later showed no pulmonary nodules, reinforcing the surveillance strategy.

Read the full case study: https://bit.ly/40iYHkd

02/17/2026

Case study highlights how CyPath® Lung reduces patient anxiety and supports physician confidence in assessment of benign pulmonary nodules.

This data supports evidence-based surveillance decisions, reinforces guideline-consistent follow-up intervals and may help reduce invasive procedures on benign nodules. Read the findings: https://bit.ly/4sgkuoX

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

https://bioaffinitytech.com/

Alerts

Be the first to know and let us send you an email when bioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Featured

Psych Dimensions

Want your practice to be the top-listed Clinic in San Antonio?